<DOC>
	<DOC>NCT00782184</DOC>
	<brief_summary>Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40). After 6 weeks of treatment, the percent reduction in low-density lipoprotein cholesterol (LDL-C) will be assessed and compared between the two treatment groups.</brief_summary>
	<brief_title>Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Participants who are either statin naive or on approved lipid lowering therapy for 6 weeks prior to study initiation Participant meets Adult Treatment Panel (ATP) III High Risk criteria Females who are pregnant or breastfeeding Participant consumes more than 14 alcoholic beverages per week Participant has been treated with an investigational drug within the last 30 days Participant has congestive heart failure (New York Heart Association [NYHA] Type III or IV) Participant has had gastric bypass Participant is newly diagnosed with type 1 or 2 diabetes Participant is Human Immunodeficiency Virus (HIV) positive Participant has a history of drug or alcohol abuse within the last 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>